ONdrugDelivery | Global Drug Delivery Industry Information & Intelligence

OCULAR

THE CHALLENGES IN DEVELOPING AND MANUFACTURING CUSTOM OPHTHALMIC INJECTOR DEVICES

Sanner's Dr Lorna Barron sets out the standards that must be met for effective drug delivery to the eye, characterising both old and new delivery routes that may be used to address the unique challenges of ophthalmic disease.

THE RETINAL DELIVERY BOTTLENECK: WHY TODAY’S TOOLS WON’T SCALE

Dr David Cottenden and Benjamin Hatton examine the rapid shift towards cell and gene therapies in ophthalmology, indicated by current pharmaceutical pipelines, and reveal a potential delivery crisis – today’s surgical capacity cannot support what the pipeline demands. Considering this, they explore why a radical rethink of retinal delivery tools could unlock scalable access to the retina.

SHL MEDICAL AND BAYER: A COLLABORATIVE APPROACH TO ADVANCING INTRAVITREAL PAEDIATRIC DOSING

Andreas Kalitzki, Samuel Wyler and Seda Aksel explain how Bayer and SHL Medical collaborative efforts are enhancing paediatric intravitreal injections through evidence-based dosing strategies and clinically validated therapies using SHL Medical’s Micro Dosing Device technology.

MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION – LAUNCHING AT DCAT WEEK

MY STERINITY NASAL PLATFORM: A PRODUCT OF COLLABORATION – LAUNCHING AT DCAT WEEK

SGD Pharma discusses the advantages and benefits of the company’s recent partnership with Prince Sterilization Services, with a focus on the first product platform developed based on this collaboration – the My Sterinity Nasal platform of Type I glass primary containers for sensitive, long-term nasal therapeutics. Additionally, SGD Pharma highlights its presence at DCAT Week 2026.

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell

West Pharmaceutical Services

EMPOWERING VISION FOR THE FUTURE: ADVANCED CONTAINMENT SOLUTIONS FOR OPHTHALMIC APPLICATIONS

Dr Linara Cornell, Dr Manali Potnis and Dr Krishnendu Khan review the current landscape and challenges associated with delivery systems for ophthalmic applications, and how West Pharmaceutical Services plays a critical role in this specialised industry by providing high quality prefilled syringe components and systems that meet the stringent requirements for these sight-saving therapies.

NOVELIA<sup>®</sup>: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Séverine Duband

NOVELIA^®: ENABLING THE NEXT GENERATION OF PRESERVATIVE-FREE MULTIDOSE OPHTHALMICS

Severine Duband and Natalia Zabala discuss the role of multidose preservative-free eyedroppers in the ophthalmic market, highlighting the advantages of Nemera’s Novelia^® platform, including its non-return valve system, the sustainability of multidose delivery and the platform’s growing success within the Chinese market.

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

INTRAVITREAL INJECTIONS – WHAT IS CAUSING PATIENTS TO DISCONTINUE THERAPY AND WHY IS IT SO HARD TO FIX?

Gregg Draudt considers the significant issue of treatment discontinuation in intravitreal therapies, digging into the root causes of poor adherence and what will be required to reverse this trend in a way that caters to the full range of stakeholders, who often have contradictory requirements.

ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT

ADDRESSING OCULAR SAFETY CHALLENGES IN ADC DEVELOPMENT

Dr Tina Rogers discusses antibody-drug conjugates and their potential in direct targeting and treatment of cancers, going further to assess the risks of these treatments and how they can be mitigated.

Sustainable Packaging and Patient-Centric Design

Cambridge Design Partnership

Sustainable Packaging and Patient-Centric Design

Steve Augustyn and Jon Powell discuss a range of key topics in the drug delivery industry, including design complexity, sustainable materials and patient-centric design.

Cardiometabolic Treatments, Rare Diseases, Variable Dosing, and Quanta

Cardiometabolic Treatments, Rare Diseases, Variable Dosing, and Quanta

Bart Burgess discusses some of the key areas for innovation in the industry, such as rare diseases and moving away from variable dosing solutions, and introduces Quanta – SHL's latest product offering.

Automated Testing to Decrease Time-To-Market

Landon Goldfarb

Automated Testing to Decrease Time-To-Market

Landon Goldfarb highlights the advantages conferred by Instron's Cobot automated testing system at both the design verification and production stages of autoinjector development.

Sustainability, Balancing Priorities, and Bringing New Solutions to Market

Sustainability, Balancing Priorities, and Bringing New Solutions to Market

Steven Kaufman discusses the return of sustainability to the centre of drug delivery conversation and how Eco-Inject's novel autoinjector brings fresh thinking to the sector.

Dual-Chamber Syringes, New Partnerships, and Speed-to-Market Pressures Shape 2026

Credence MedSystems

Dual-Chamber Syringes, New Partnerships, and Speed-to-Market Pressures Shape 2026

John Merhige outlines his key themes shaping drug delivery in 2026: new momentum from a dual-chamber syringe fill-finish collaboration, a newly announced commercial supply agreement with a major global pharma company, and growing pressure to deliver increasingly complex molecules faster and more efficiently.

Challenges, Trends, and Recognising Innovation

Laura Armstrong

Challenges, Trends, and Recognising Innovation

Laura Armstrong discusses the challenges and trends currently impacting the drug delivery and pharmaceutical packaging industry.

ARE YOU STILL PIECING TOGETHER YOUR PREFILLABLE SYRINGE SYSTEM OR ARE YOU ALREADY FILLING IT?

PREFILLED SYRINGES

Dr Bettine Boltres

West Pharmaceutical Services

ARE YOU STILL PIECING TOGETHER YOUR PREFILLABLE SYRINGE SYSTEM OR ARE YOU ALREADY FILLING IT?

Dr Bettine Boltres introduces the West Synchrony™ prefillable syringe system, explaining how the device, as a single comprehensive package, minimises regulatory complications and delays.

TRENDS FOR 2026

TRENDS FOR 2026

A new reality is forming as we enter 2026 – it will not be “business as usual”. Geopolitical forces in the largest market for pharmaceuticals, the US, are likely to mean substantial changes. Here, Tom Oakley and Alex Vasiev cover those changes, the incretin juggernaut and the march of technical progress with “minitablet” dispensers, large-volume injectors and dual-chamber devices.

ACCELERATING PATIENT-CENTRIC THERAPIES FROM DEVELOPMENT TO DELIVERY

INDUSTRIALISATION

Justin Schroeder

PCI Pharma Services

ACCELERATING PATIENT-CENTRIC THERAPIES FROM DEVELOPMENT TO DELIVERY

Justin Schroeder outlines its product service offering to the drug delivery industry, including sterile fill-finish services, drug-device combination product development and testing, clinical and commercial device assembly, packaging, storage and distribution, among other services.

TIME TO MARKET: INCREASED CUSTOMER VALUE THROUGH GLOBAL RAMP-UP EXCELLENCE

PREFILLED SYRINGES

Baumann Medical

TIME TO MARKET: INCREASED CUSTOMER VALUE THROUGH GLOBAL RAMP-UP EXCELLENCE

David Pircher and Leander Moser discuss the advantages of having a global presence, which combines both local expertise and technical excellence with worldwide co-ordination of supply to deliver consistent and quality solutions.

Interview: Developing Wearable Injectors

EdgeOne Medical

Interview: Developing Wearable Injectors

Liat Shochat discusses her extensive experience in wearable drug delivery device development, covering the various challenges that arise from the inherent complexity of these devices, even with multiple successful wearable devices on the market, as well as the best way to engage with contract development organisations such as EdgeOne Medical.

EARLY AUTOMATION CONSIDERATIONS FOR THE DEVELOPMENT OF DRUG DELIVERY COMBINATION PRODUCTS

PREFILLED SYRINGES

Asmita Khanolkar

EARLY AUTOMATION CONSIDERATIONS FOR THE DEVELOPMENT OF DRUG DELIVERY COMBINATION PRODUCTS

Asmita Khanolkar and Al Neumann, uncover the manufacturing strategies that can be used to achieve design for automation, scale-up and sustainable solutions for clinical and commercial launch, describing the gains to be made in manufacturing efficiency when using small, automated work cells.

FRICTIONLESS ENGAGEMENT: HOW GX INMONIT™ CAN SIMPLIFY SELF-INJECTION AND STRENGTHENS PATIENT ADHERENCE

FRICTIONLESS ENGAGEMENT: HOW GX INMONIT™ CAN SIMPLIFY SELF-INJECTION AND STRENGTHENS PATIENT ADHERENCE

Dr Giacomo Bruno and Simon Buerdel consider the causes of patient non-adherence and its subsequent effects on healthcare systems, going on to present the solutions created by Gerresheimer to address the patient experience across treatment types.

TESTING AUTOINJECTORS ACCORDING TO ISO 11608-5 TO INCREASE RELIABILITY AND BOOST EFFICIENCY

PREFILLED SYRINGES

Wolfgang Moersch

TESTING AUTOINJECTORS ACCORDING TO ISO 11608-5 TO INCREASE RELIABILITY AND BOOST EFFICIENCY

Wolfgang Moersch discusses the role of automation in testing injection devices – including autoinjectors, pen injectors and on-body injectors – and how advanced testing software and robotics solutions can provide more accurate and consistent testing results.

SAFETY BY DESIGN FOR DRUG DELIVERY DEVICES

PREFILLED SYRINGES

Dr Stefan Schreiber

Scherdel Medtec

SAFETY BY DESIGN FOR DRUG DELIVERY DEVICES

Professor Stefan Schreiber, Dr Theo Wember and Sebastian Block discuss how using Design of Experiments methodology can provide insights into the manufacturing process of power springs that can enable manufacturers to more robustly control variables and produce more consistent outputs.

FROM CONCEPT TO SERIES PRODUCTION – ACCELERATING INDUSTRIALISATION IN MEDTECH

PREFILLED SYRINGES

Matthias Müller

FROM CONCEPT TO SERIES PRODUCTION – ACCELERATING INDUSTRIALISATION IN MEDTECH

Matthias Müller and Sven Müller discuss Contexo and Probotec's combined approach to scaling drug-device combination products from laboratory prototypes to fully validated GMP commercial-scale production lines.

Interview: New But Not News – A Smooth Transition to USP <382> with Established Expertise

Dr Aurelie Rebuffet

BD (Becton Dickinson & Company)

Interview: New But Not News – A Smooth Transition to USP <382> with Established Expertise

Dr Aurélie Rebuffet and Virginie Jeymond, discuss the new requirements set out in the US Pharmacopeia (USP) Chapter <382>, including the shift towards assessing the drug-device combination product as a holistic whole and how ZebraSci and BD can support pharma companies in complying with USP <382>.

BUILDING STRATEGIC PARTNERSHIPS FOR EARLY-STAGE DRUG DELIVERY DEVICE TESTING

Landon Goldfarb

BUILDING STRATEGIC PARTNERSHIPS FOR EARLY-STAGE DRUG DELIVERY DEVICE TESTING

Landon Goldfarb considers the importance of relationships between formulation and delivery teams for pharmaceutical innovation, highlighting a framework to differentiate between an equipment supplier and a testing partner, outlining the system capabilities and organisational competencies required to create effective early device-development teams.

REDEFINING THE ROLE OF PACKAGING IN A DEMANDING PHARMACEUTICAL LANDSCAPE

CONFERENCE SHOWCASE

Sherma Ellis Daal

REDEFINING THE ROLE OF PACKAGING IN A DEMANDING PHARMACEUTICAL LANDSCAPE

Ahead of this year’s Pharmapack Europe conference on Jan 21–22, 2026, Sherma Ellis Daal discusses the role of packaging and drug delivery systems in the wider pharmaceutical industry, offering insights on how key trends and pressures are changing thinking and redefining what makes a successful project.

1
2
3
…
70
Next

See what ondrugdelivery's readers and contributors think

Abby Lockwood
Consultant
Plan Strategic

ONdrugDelivery Magazine is a great resource that brings a lot of value to the work my team and I are doing in the area of drug delivery. The device-specific content as well as the broader discussions surrounding industry trends and issues are extremely informative and very well written.

Dr Cristian Vilos

I‘m working on the development of microparticles for the release of veterinary antibiotics, and polymeric nanoparticles for siRNA and chemotherapeutic delivery. ONdrugDelivery has been a very usefull platform to connect the scientific research, and marketed drug development.

Li-Chun Tsou, PhD, MBA
Principal Engineer
Merck & Co

Your website and publication is a great asset for me. I’d recommend your publication to my colleagues. I am sure that we will gain knowledge and update information through your timely report. Thanks for making it available.

Matt Kempton
Snr Project Engineer
Corning Incorporated

I am extremely impressed with the comprehensive presentation of information and problem/solution points detailed ... Kudos to you for an extremely well written article with succinct and robust scientific body of knowledge.

Top